Citation

Socias ME, Choi JC, Lake S, Wood E, Valleriani J, Hayashi K, Kerr T, Milloy MJ. Drug Alcohol Depend. 2021; 221: e108547.

Copyright

(Copyright © 2021, Elsevier Publishing)

DOI

10.1016/j.drugalcdep.2021.108547

PMID

unavailable

Abstract

The authors sincerely regret that an incomplete statement of competing interests was published with the initial version of this article. The complete statement of competing interests that should have accompanied our article is: "JV was appointed as Director of Global Patient Advocacy for Canopy Growth in January 2020, after the completion of the manuscript. She did not contribute to the study's methodological design or data analysis. After the submission of the manuscript, M-JM and ES were awarded funds by the Canadian Institutes of Health Research for a study of the safety and feasibility of co-dispensing tetrahydrocannabinol alongside methadone; Tilray, a licensed producer of cannabis, will provide study drug. M-JM declares no other competing interests, e.g., employment, consultancies, stock ownership, honouraria, paid expert testimony, patents, grants or other funding. At the time of submission and continuing to the present, EW is the chief medical officer of Numinus Wellness, a company interested in researching and providing psychedelic-assisted psychotherapies and conducting commercial testing of psychoactive products including cannabis. He is also supported by a Canada Research Chair. Other authors declare no competing interests."

The authors apologize for these oversights and believe these relationships did not impact the scientific work presented, but provide these disclosures to ensure the reader can draw their own conclusions. The substantial administrative and research disruption caused by the COVID-19 pandemic impacted our disclosures, although we acknowledge and appreciate this is not a sufficient explanation for this oversight.

Language: en